Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $63.19 USD
Change Today +0.09 / 0.14%
Volume 1.4M
As of 8:04 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (STJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/15 - $80.84
52 Week Low
10/16/14 - $54.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ST JUDE MEDICAL INC (STJ)

st jude medical inc (STJ) Related Businessweek News

View More BusinessWeek News

st jude medical inc (STJ) Details

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems and cardiac resynchronization therapy defibrillator devices to treat patients suffering from lethal heart conditions, such as sudden cardiac arrest or heart failure. It also provides pacemakers, which deliver low-voltage electrical impulses to stimulate a heartbeat for patients whose hearts beat too slowly; and atrial fibrillation products comprising electrophysiology, introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, renal denervation technology and vascular plugs, optical coherence tomography imaging products, and other vascular accessories, as well as CardioMEMS, a heart failure monitoring device. Further, it provides structural heart products, including transcatheter aortic heart valves, various surgical heart valve repair and replacement products, and transcatheter structural heart defect devices; and neuromodulation products, such as spinal cord stimulation and radiofrequency ablation to treat chronic pain, as well as deep brain stimulation to treat movement disorders. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in St. Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/15
Founded in 1976

st jude medical inc (STJ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President of...
Total Annual Compensation: $468.8K
Chief Operating Officer
Total Annual Compensation: $788.3K
President of International Division
Total Annual Compensation: $752.4K
Group President
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

st jude medical inc (STJ) Key Developments

St. Jude Medical Inc. and U.S. Bank National Association Enter into Fifth Supplemental Indenture

On September 23, 2015, St. Jude Medical Inc. and U.S. Bank National Association, as trustee (the trustee and, together with the company, the parties), entered into a Fifth Supplemental Indenture to the Indenture (the indenture), dated as of July 28, 2009, by and between the parties. The Fifth Supplemental Indenture relates to the company's 2.000% Senior Notes due 2018 (the 2018 Senior Notes), 2.800% Senior Notes due 2020 (the 2020 Senior Notes) and 3.875% Senior Notes due 2025 (the 2025 Senior Notes and, together with the 2018 Senior Notes and the 2020 Senior Notes, the Notes).

St. Jude Medical Inc. CE Mark for the New Infinity Deep Brain Stimulation System and Directional DBS Lead

St. Jude Medical Inc. announced CE Mark approval for the St. Jude Medical Infinity Deep Brain Stimulation (DBS) System and directional DBS lead. The St. Jude Medical Infinity DBS system, which will be available in two sizes, is the only upgradeable DBS system available to patients battling movement disorders. The system uses Bluetooth wireless technology to communicate between the St. Jude Medical Infinity DBS platform and Apple digital devices used as patient and physician controllers. Combined, the features of the system provide an improved, more intuitive experience for patients suffering from Parkinson’s disease, tremor and dystonia, a disorder which causes involuntary muscle contractions. Movement disorders are neurologic conditions that develop as communications breakdown throughout a patient’s central nervous system, leading to a debilitating lack of muscle control, involuntary movement, and reduced coordination. With no proven cure, treatments for movement disorders often focus on alleviating the symptoms associated with each condition to improve quality of life. Combined, Parkinson’s disease, dystonia and tremor represent the three most common movement disorders in the world. DBS systems deliver mild electrical pulses to specific targets in the brain to stimulate the structures involved in motor control. The systems consist of a surgically-implanted neurostimulator that generates the electrical pulses and thin wires called leads which carry the pulses to the brain to influence the irregular nerve signals responsible for many of the symptoms of movement disorders. Conventional DBS leads have a limited ability to steer current directionally, which can be challenging for physicians trying to provide effective stimulation to specific areas of the brain. The St. Jude Medical Infinity DBS system operates in conjunction with the company’s newly-approved directional DBS lead, which allows physicians to shape the therapy to a patient’s specific needs while avoiding stimulation to areas that may create side effects. St. Jude Medical designed the Infinity platform and directional lead based on physician feedback demonstrating a clear need for improved stimulation targeting, device longevity and a maintenance free, non-rechargeable battery. The St. Jude medical Infinity DBS system was designed to transform the standard of care for movement disorder patients by incorporating a number of patient-centric features. Because the Infinity system is upgradeable, St. Jude Medical offers patients the ability to retain access to the latest technology and therapy options and new modes of stimulation as they are approved via software upgrades, avoiding the need to undergo repeat surgery. St. Jude Medical has also developed technology to allow patients with existing DBS systems from any manufacturer to replace their existing system to take advantage of the advancements enabled by the Infinity system. In addition, patients will now be provided an Apple iPod Touch digital device that allows them to easily manage their therapy. Physicians will program their patient’s devices through an iPad Mini digital device. The St. Jude Medical patient and physician programmers use Bluetooth wireless technology, providing a secure, safe, and wireless experience.

St. Jude Medical Inc. Gains European CE Mark for 27 MM & 29 MM Portico TAVR Valves to Complete a Full Portfolio of Portico Sizing Options for Physicians Treating Patients with Aortic Stenosis

St. Jude Medical Inc. announced the European CE Mark approval for the 27 mm and 29 mm Portico Transcatheter Aortic Valve Replacement System. The approval follows previous approvals of the 23 mm and 25 mm Portico valves, allowing St. Jude Medical to offer physicians an expanded range of fully repositionable, retrievable TAVR valve sizes. The Portico valve accommodates a patient’s native anatomy with diameters ranging from 19 to 27 mm. Aortic stenosis is one of the most common forms of cardiovascular disease in the world, and develops as the aortic heart valve becomes calcified, narrowing the valve and preventing a complete opening. Over time, aortic stenosis disrupts the blood flow from the heart, which causes the heart to pump harder and results in weakening. TAVR procedures provide physicians an additional treatment option for patients with severe aortic stenosis who are considered high risk for open heart surgery. The Portico system was developed to simplify TAVR procedures for physicians by improving control, ease of use and accuracy over other commercially-available TAVR valves. The system offers the ability for the Portico valve to be fully recaptured and repositioned prior to full deployment and release from the delivery system, providing physicians more options to place the valve in the targeted location. The Portico system has also demonstrated low rates of permanent pacemaker utilizations post valve implant as a result of heart block and was designed to minimize the risk of paravalvular leak (a leakage of blood caused by a space between the heart tissue and a replacement valve). During a transfemoral implant procedure, the Portico valve is delivered by catheter through the femoral artery in the leg and is positioned while the patient’s heart continues to beat. Use of the Portico valve alleviates the use of cardiopulmonary bypass, which involves a machine taking over a patient’s heart and lung function during surgery and can cause added strain on an already frail heart. The 23 mm the 25 mm Portico Transcatheter Aortic Heart Valve are both CE Mark approved and commercially available in Europe. In the United States, the Portico valve is currently being evaluated in a clinical trial through an investigational device exemption by the U.S. Food and Drug Administration. The Portico IDE trial originally launched in May 2014, and is designed to support U.S. approval of the Portico system.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $63.19 USD +0.09

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $16.79 USD -0.03
CR Bard Inc $187.02 USD +0.20
Olympus Corp ¥3,840 JPY -15.00
Smith & Nephew PLC 1,132 GBp +4.00
Zimmer Biomet Holdings Inc $95.44 USD +0.55
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 17.4x
Price/Sales 3.2x
Price/Book 4.6x
Price/Cash Flow 15.6x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at